CRISPR Therapeutics Reports Q1 Loss of $1.28 Per Share
Summary
CRISPR Therapeutics AG announced a first-quarter loss of $1.28 per share. This earnings report provides the latest financial performance update for the company, following its 2025 10-K which reported a widened net loss. While the headline does not specify if this loss met or missed analyst expectations, it is a critical data point for investors evaluating the company's financial health and operational trajectory. This update comes after recent shareholder proposals for increased share capital, highlighting ongoing corporate activity. Traders will now scrutinize the full earnings details for insights into revenue, cash burn, and pipeline progress.
At the time of this announcement, CRSP was trading at $53.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $33.03 to $78.48. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.